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Human tissue transglutaminase (TGM2) is a calcium-
dependent crosslinking enzyme involved in the post-
translational modification of intra- and extracellular
proteins and implicated in several neurodegenera-
tive diseases. To find specific inhibitors to TGM2,
two structurally diverse chemical libraries (LOPAC
and Prestwick) were screened. We found that
ZM39923, a Janus kinase inhibitor, and its metabolite
ZM449829 were the most potent inhibitors with IC50
of 10 and 5 nM, respectively. In addition, two other in-
hibitors, including tyrphostin 47 and vitamin K3, were
found to have an IC50 in the micromolar range. These
agents used in part a thiol-dependent mechanism to
inhibit TGM2, consistent with the activation of TGM2
by reduction of an intramolecular disulfide bond.
These inhibitors were tested in a polyglutamine-
expressing Drosophila model of neurodegeneration
and found to improve survival. The TGM2 inhibitors
we discovered may serve as valuable lead com-
pounds for the development of orally active TGM2
inhibitors to treat human diseases.
INTRODUCTION
Tissue transglutaminase (TGM2) is a member of the transgluta-
minase (TG, E.C. 2.3.2.13, protein-glutamine g-glutamyltransfer-
ase) family, known to catalyze inter- and intramolecular cross-
linking between specific glutamine g-carboxamide groups and
3-amino groups in lysine and free primary amines (TGase)
(Folk, 1983; Greenberg et al., 1991; Lorand and Graham,
2003). TGM2 is ubiquitously expressed and in almost all tissues
(Folk, 1983; Greenberg et al., 1991; Lorand and Graham, 2003),
and is found on the cell surface—membrane bound—in the ex-
tracellular matrix, cytoplasm, and nucleus of cells (Greenberg
et al., 1991; Lorand and Graham, 2003). Extracellular TGM2 in-
teracts with integrins and fibronectin, and is involved in cell
movement, adhesion, and proliferation (Lorand and Graham,Chemistry & Biology 15, 969–92003). Intracellular TGM2 crosslinking activity is inhibited when
bound to guanosine-50-triphosphate (GTP) (Achyuthan and
Greenberg, 1987). TGM2 also functions as a G protein in adren-
ergic receptor-mediated and phospholipase C signal transduc-
tion pathways (Murthy et al., 1999; Nakaoka et al., 1994). In
addition, TGM2 can bind and hydrolyze ATP, and function as
a kinase (Lai et al., 1998; Mishra and Murphy, 2004a). Under-
standing how TGM2 can perform such diverse functions in cells
remains a challenging task, but new studies reveal the protein
can exist in two different conformations (Pinkas et al., 2007).
When bound to GTP/GDP, the protein adopts a compact pro-
tease-resistant conformation. When a substrate interacts with
the protein, disulfide bond is formed and the enzyme has an
elongated open conformation that exposes the active site (Pin-
kas et al., 2007). The active site pocket of TGM2 is composed
of a catalytic triad of C277-H335-D358 (Liu et al., 2002), and the
first rapid step in catalysis involves the formation of a transi-
tional thioester bond between active site C277 and the Q sub-
strate (Case and Stein, 2003) that requires a specific set of in-
teractions that potentially could be disrupted by a small
molecule.
TGM2 is an important therapeutic target for several neurode-
generative diseases, including Huntington’s, Alzheimer’s, and
Parkinson’s diseases (Malorni et al., 2008; Muma, 2007).
TGM2 crosslinking alters the solubility, structure, and function
of proteins that express a polyglutamine repeat (Lai et al.,
2004), such as alpha-synuclein (Andringa et al., 2004) and Tau
(Tucholski et al., 1999). Neuronal TGM2 contributes to distinctive
pathological features of many neurodegenerative diseases me-
diated by central nervous system (CNS) expression of polyQ
protein (Arrasate et al., 2004; Konno et al., 2005). Studies using
TGM2 KO mice mated with Huntington’s disease (HD-prone
mice) showed that TGM2 plays a role in the neurodegenerative
progression of polyQ disease (Mastroberardino et al., 2002). Be-
cause polyQ disease is a fatal illness that has no known therapy,
efforts to treat this disorder are needed. Furthermore, other dis-
eases where there is formation inside and outside the CNS may
also benefit from the development of orally active TGM2 inhibi-
tors. Given the involvement of TGM2 in such severe diseases,
the development of small-molecule inhibitors capable of inhibit-
ing TGM2 protein crosslinking is warranted. In this study, we
used a high-throughput screening assay to determine whether78, September 22, 2008 ª2008 Elsevier Ltd All rights reserved 969
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and were active in the CNS when administered orally.
In an effort to identify inhibitors of TGM2, we screened two
structurally diverse chemical libraries, including LOPAC
(Sigma-Aldrich; St. Louis, MO) and Prestwick (Prestwick Chem-
ical; Illkirch, France). The LOPAC library contains 1,280 pharma-
cologically active compounds that span a broad range of biolog-
ical arenas. This library contains marketed drugs, failed
development candidates, and ‘‘gold standards’’ that have
well-characterized activities. The Prestwick Chemical Library
consists of 880 carefully selected compounds, which are highly
diverse in structure and cover many therapeutic areas. Our
approach to identify inhibitors to a new therapeutic target could
significantly shorten the interval between preclinical and clinical
studies (Chong and Sullivan, 2007). In this study, we report three
chemicals that inhibit TGM2 in vitro and are bioactive in vivo.
These inhibitors bound tightly to TGM2, and inhibition was mod-
ified by the reducing agent DTT, suggesting a disulfide bridge
plays a critical role in their mechanism of action. Our data
strongly suggest that these three chemicals could be used as
scaffold structures for designing more specific TGM2 inhibitors
that are orally active and could be used to treat CNS disorders
in which TGM2 plays a role.
RESULTS
Screening of LOPAC and Preswick Chemical Libraries
Initial screening was performed using a continuous solution-
phase fluorescent KXD incorporation assay performed at 6 mg/ml
of purified recombinant human TGM2 in the presence of 10 mM
Ca+2 in a 96-well microtiter plate designed for robotic high-
throughput screening (see Experimental Procedures). Initially,
20 hits were identified based on inhibition of R90% of TGase/
TGM2 activity at 50 mM of candidate inhibitor, excluding the
well-characterized inhibitors cystamine (CYST) and iodoaceta-
mide, which target the active site Cys-SH of TGM2. These chem-
icals were more potent than GTP, as 50 mM of GTP inhibited
%25% of TGase/TGM2 activity under the same conditions. To
eliminate fluorescence interference, chemicals were subjected
to a secondary screening using a colorimetric BP incorporation
assay (see Experimental Procedures). A total of nine inhibitors
were found to have IC50 % 20 mM (Tables 1 and 2). These
inhibitors can be classified as kinase-, phosphatase-, or qui-
none-related inhibitors (Tables 1 and 2). The kinase- and
phosphatase-related inhibitors target kinases and phospha-
tases, including c-Raf-1 kinase (Ser/Thr kinase), Janus kinase
3 (JNK3, a Tyr kinase), EGFR tyrosine kinase, calmodulin
(CAM) kinase, and Cdc25 tyrosine phosphatase. Several of
these inhibitors were developed to target GTP (GW5074, tyr-
phostin 47, Me-3,4-dephostatin) and adenosine-50-triphosphate
(ATP) binding sites with guanine (and adenine) as backbone
structures. The naphthoquinone-related TGM2 inhibitors
(NSC95397, b-lapachone, and menadione, or vitamin K3 as is it
also known) can be classified into 1,2-naphthoquinone (b-lapa-
chone) or 1,4-naphthoquinone (NSC95397 and vitamin K3) deriv-
atives (Table 2). Reactive blue 2 is an anthraquinone derivative.
ZM 39923, initially designed to inhibit Janus kinases (Luo and
Laaja, 2004), was found to be a potent inhibitor of TGM2 with
IC50 of 10 nM when the assay was performed in the absence970 Chemistry & Biology 15, 969–978, September 22, 2008 ª2008 Eof DTT (Tables 1 and 2). ZM 449829 (Figure 1 and Table 3), the
metabolite of ZM 39923 (Luo and Laaja, 2004), was an even
more potent inhibitor with an IC50 of 5 nM.
Effects of Triton X-100 on Inhibitors in Inhibiting
TGase/TGM2 Activity
To eliminate compounds that were nonspecific or low affinity, we
investigated the effects of Triton X-100. Small moleculesmay form
nonspecific submicrometer aggregates. A reversible physical as-
sociation between aggregates and enzyme could produce a false
positive in the screening assay (McGovern et al., 2003). Small ag-
gregates are eliminatedby 0.01%TritonX-100 treatment (McGov-
ern et al., 2003), and we found the potency of GW 5074, Rotterin,
reactive blue 2, and b-lapachone were significantly reduced by
0.02%Triton X-100 treatment (Tables 1 and 2), whereas ZM39923
was not changed. In contrast, the IC50 of Me-3,4-dephostatin, tyr-
phostin 47, NSC95397, and vitamin K3 were increased by 1.3-fold
to 2.5-fold after Triton X-100 treatment (Tables 1 and 2).
Effects of Tyrphostins-Related Compounds on TGM2
Activity
Tyrphostins are a class of synthetic compounds that have been
identified as the inhibitors of EGF receptor tyrosine kinase
(Wolbring et al., 1994). There is a comprehensive collection of
tyrphostin analogs in the LOPAC library (see Tables S1–S4 avail-
able online). We identified Me-3,4-dephostatin and tyrphostin 47
as two potent inhibitors in tyrphostin-related compounds with
IC50 < 20 mM (Table 1).
Effects of Reducing Agent on Inhibition of TGM2Activity
Because active TGM2 requires free sulfhydryl (SH) groups to
be active, we tested the effect of reducing agents on TGM2
inhibition. We found that the inhibition of vitamin K3, vitamin K2
(MK4), NSC95397, T7540 (tyrphostin 47), ZM39923, and
ZM449828 was reduced by 23-, 17-, 50-, 17-, 300-, and
4,000-fold, respectively, in the presence of DTT (Table 3).
Effects of Naphthoquinone Analogs on Inhibition
of TGase Activity
To investigate which functional groups in naphthoquinones were
important for inhibition of TGase/TGM2 activity, a series of 1,4-
naphthoquinone analogs were investigated at a concentration
of 15 mM (Table S5). For the 1,4-naphthoquinone analogs, a
methyl group (vitamin K3) or no substitution (152757) at the C-2
position appeared to be important in inhibiting TGase activity
(Table S5). Substitution with other groups reduced the inhibitory
potency (Table S5). The side chain at positions 2 and/or 3 in naph-
thoquinone were also investigated and were less potent, with the
exception of MK4, a naturally occurring vitamin K2 analog with
a geranylgeranyl side chain (Table S5). Vitamin K3 and vitamin
K2 inhibited TGase activity to a similar extent, whereas vitamin
K1 (phylloquinone) did not (Table S5). Ubiquinone (CoQ10), a com-
monly used antioxidant, was not an inhibitor of TGM2.
Calcium Ions Lead to Irreversible Inhibition of TGM2
To determine whether the inhibitors would produce reversible in-
hibition, dialysis experiments were performed (Figure 2A). When
TGM2 was incubated with inhibitors in the absence of Ca+2,
ZM39923, vitamin K3, vitamin K2, and Me-3,4-dephostatinlsevier Ltd All rights reserved
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Name IC50 (mM) IC50 (Triton
#) Target Structure
G6416 (GW5074) 15 ± 6 50 ± 5 cRaf kinase
Z4626 (ZM 39923) 0.01 ± 0.01 No Change Janus Kinase 3
R5648 (Rottlerin) 20 ± 10 > 50 pKC & CaM III Kinase
M9440 (Me-3,4-dephostatin) 18 ± 8 36 ± 10 Tyrosine Phosphatase
T7540 (Tyrphostin 47) 3 ± 3 4 ± 2 EGFR Tyrosine Kinase
1. The activities were determined by BP-assay in the absence of DTT and represent the average of two triplicate experiments.
2. #: 0.02% Triton was used in the assay.were reversible inhibitors (Figure 2A). In contrast, TGM2 activity
after incubation with ZM449829, tyrphostin 47, and NSC95397
were only partially reversible (Figure 2A). In the presence of
Ca+2, the inhibition was irreversible (Figure 2B) in all cases.
Effects of Inhibitors on Crosslinking Activity of Blood
Coagulation Factor XIIIa (FXIIIa)
We investigated whether inhibitors could modify the plasma pro-
tein FXIIIa, a member of the transglutaminase family (GreenbergChemistry & Biology 15, 969–9et al., 1991; Lorand and Graham, 2003). FXIIIa is formed after
thrombin cleavage and release of activation peptides and the
dissociation of factor XIII B chains (Lorand and Graham, 2003).
ZM39923, Me-3,4-dephostatin, tyrphostin 47, and NSC96397
showed significant inhibition of crosslinking activity with 15 mM
of the chemical in the absence of DTT (Table 4). FXIIIa activity
was also partially restored by DTT (Table 4). The IC50 of the se-
lected inhibitors are presented in Table 4 and are in the same
range and pattern of inhibition for TGM2.78, September 22, 2008 ª2008 Elsevier Ltd All rights reserved 971
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Name IC50 (mM) IC50 (mM) (Triton
#) Target Structure
N1786 (NSC95397) 1 ± 0.5* 2.5 ± 0.6* Cdc25 Phosphatase
L2037 (b-lapachone) 5 ± 3 20 ± 2 Anti-Cancer
R115 (Reactive Blue 2) 1.8 ± 0.4* > 50* P2Y Receptor
Menadione (Vitamin K3) 2.2 ± 0.8* 5.5 ± 2* ReDox
*Performed W/O DTT.
#: 0.02% Triton was used in the assay.
1. The activity was determined by BP-incorporation assay and represent the average of two triplicate experiments.Effects of Inhibitors on Proteolysis of TGM2
GTP binds to TGM2 and renders the molecule protease resis-
tant, whereas ATP binding has less effect. TGM2 was incubated
with 100 mM of the inhibitors, and trypsin proteolysis was moni-
tored by SDS-PAGE. (Figure S1). Tyrphostin 47-treated TGM2
was protected from proteolysis in a pattern similar to GTP. All
other compounds showed limited proteolytic protection and
had patterns similar to ATP (Figure S1).
Effects of Chemical Inhibitors on GTP Binding of TGM2
The GTP binding properties were validated using the fluorescent
GTP analog BODIPY-FL-GTP. Binding of this analog to TGM2972 Chemistry & Biology 15, 969–978, September 22, 2008 ª2008 Eproduces a dramatic enhancement of fluorescence intensity
(Figure 3). GTP and GDP compete with BODIPY-GTP and re-
duced fluorescent intensity (Figure 3A). Tyrphostin 47 was able
to compete with GTP for the binding (Figures 3B and 3C), sug-
gesting that they bind to TGM2 in a similar manner.
Effects of Chemicals That Altered TGM2 Activity
on a Drosophila Model of Human polyQ Disease
(Machado-Joseph Disease)
Because the long-term goal of our project is to develop orally ac-
tive agents to inhibit TGM2 for use in neurodegeneration, we
tested them in a Drosophila melanogaster model of a polyQlsevier Ltd All rights reserved
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Arrasate et al., 2004). Expression of themutant human polyQ dis-
ease gene in Drosophila confers a phenotype similar to the hu-
man disease with late-onset, progressive neural degeneration
(Nagai et al., 2007). Drosophila, which carried the expanded
polyQ (78 glutamine repeats, Q78), were designated as disease
flies; flies that expressed the Q27 protein were controls and con-
sidered normal flies. The untreated flies expressing Q78 dis-
played the shortest survival, and the disease became manifest
during the middle of their life span. Cystamine (Cyst), an orally
active TGM2 inhibitor, served as positive treatment modality,
as it has been effective in mouse model of polyQ disease (De-
deoglu et al., 2002; Karpuj et al., 2002). Cyst had a beneficial ef-
fect in this model, although it was not as effective as ZM39923,
Me-3,4-dephostatin (Me), or NSC95397 in preventing early
death (Figure 4). Vitamin K3 did not function as an active agent
in rescuing the disease flies.
DISCUSSION
TGM2 is being considered as a therapeutic target for the treat-
ment of several diseases. To date, there are few reports of using
an orally active TGM2 inhibitor to modify TGM2-based disease
process. We screened the LOPAC and Prestwick libraries and
discovered candidate compounds that were potent inhibitors
of TGM2 protein crosslinking in vitro and inhibited neurodegen-
Figure 1. Structures of ZM39923 and ZM449829
Table 3. Effects of DTT on Inhibition of TGase/TGM2
10 mM DTT W/O DTT
Menadione (Vit. K3) > 50 2.2 ± 0.8
Menaquinone (Vit. K2 or MK4) > 50 3 ± 2.8
NSC 95397 (N1786) > 50 1 ± 0.5
Tyrphostin 47 (T7540) > 50 3 ± 3
ZM 39923 (Z4626) 3 ± 0.5 0.01 ± 0.01
ZM 449829 20 ± 5 0.005 ± 0.005
1. The activity was determined by BP-incorporation assay and represent
the average of two triplicate experiments.
2. Data represent the IC50 in mM.Chemistry & Biology 15, 969–9eration mediated by a polyQ protein expressed in the CNS.
The JAK kinases inhibitors (ZM39923 and ZM449829), EGFR
tyrosine kinase inhibitor (tyrphostin 47), phosphatase inhibitors
(Me-3,4-dephostatin and NSC95397), and naphthoquinones
Figure 2. Ca+2-Dependent Inhibition of TGase/TGM2 by Chemical
Inhibitors
TGM2 was incubated in the absence (A) or presence (B) of 1 mM Ca+2 with in-
hibitors at concentration that inhibited >95% of TGase activity. The mixture
was dialyzed in 41 of 50 mM HEPES (pH 7.5). The incubation mixtures were
used to determine TGase activity using BP incorporation assay. The standard
deviations were derived from triplicate experiments. Open bar: before dialysis;
closed bar: after dialysis.
Table 4. Effects of DTT on Inhibition of Factor XIIIa
W DTT W/O DTT
NSC 95397 (N1786) > 50 1 ± 0.5
Vitamin K3 > 50 12.5 ± 2
Tyrphostin 47 (T7540) > 20 3 ± 1
ZM 39923 (Z4626) 10 ± 2 0.025 ± 0.01
ZM 449829 > 20 0.006 ± 0.005
1. The activity was determined by BP-incorporation assay and represent
the average of two triplicate experiments.
2. IC50 in mM.78, September 22, 2008 ª2008 Elsevier Ltd All rights reserved 973
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+2-
activated form of TGM2. Our findings suggest that these inhibi-
tors target activated TGM2 and the free thiol groups that are
required for an active enzyme.
The specificity of the selected inhibitors was validated through
two completely different formats of screening assays—one that
used a soluble-phase fluorescent substrate and the other that
used a soluble and bound TGM2 substrate. Triton X-100 elimi-
nated the effects of nonspecific small-molecule aggregates
Figure 3. Fluorescent GTP Binding Assay
The fluorescence binding assay was performed in buffer B (50 mM Tris-Cl
[pH 7.5], 2 mM DTT, and 1 mM EDTA) containing 400 nM of purified enzyme
(TGM2) and 500 nM BODIPY FL-GTP. Buffer B, containing only BODIPY
FL-GTP, was used as a reference; the results represented the difference in
fluorescence upon binding to the enzymes.
(A) Effects of 150 mM of GTP, GDP, GMP, ATP, ADP, and AMP on BODIPY
FL-GTP binding.
(B) Similar to (A) but with inhibitors at 160 mM in the presence (filled bar) or
absence (open bar) of 1 mM Mg+2.
(C) Different concentrations of inhibitors (reactive blue 2 and tyrphostin 47),
GTP, and ATP were investigated for their effects on BODIPY FL-GTP binding.
At each concentration, the binding of inhibitors, GTP, or ATP to BODIPY
FL-GTP were used as background value to be subtracted from value obtained
with TGM2 binding. There are slight quenching from reactive blue 2 and tyr-
phostin 47 at concentrations higher than 40 mM.974 Chemistry & Biology 15, 969–978, September 22, 2008 ª2008 E(McGovern et al., 2003). The IC50 of ZM39923, ZM449829,
Me-3,4-dephostatin, tyrphostin 47, NSC95397, and vitamin K3
were found to have little inhibition and some enhancement after
Triton X-100 treatment (Tables 1 and 2). In contrast, GW5074,
Rottlerin, b-lapachone, and reactive blue 2 were significantly
reduced after Triton X-100 treatment, suggesting that they
formed aggregates and were not further characterized in
detail. Only the Triton X-100 resistant chemicals were analyzed
and found to mediate their inhibition by formation of disulfide
bonds.
ZM39923 was found to be a potent inhibitor of TGM2 with IC50
of 10 nM and its metabolite; ZM449829 had the lowest IC50 value
(5 nM). ZM39923 belongs to the class of 2-aminoethyl ketones
(or naphthyl ketones) that binds to the ATP-binding site of a tyro-
sine kinase, Janus kinase 3 (Luo and Laaja, 2004). ZM39923 and
ZM449829 target JAK1, JAK3, and epidermal growth factor
receptor (EGFR) with reported IC50s in the range of 4.4–7 mM
(Luo and Laaja, 2004), whereas TGM2 was inhibited in the nano-
molar range. The inhibition by ZM39923 and ZM449829 was not
due to aggregate formation or potential chelation of calcium
ions, as Ca+2 was present at 10,000-fold higher concentrations
than ZM39923.
Pinkas et al. (2007) recently crystallized the inhibitor-bound
TGM2 and found that a disulfide bond between Cys370 and
Cys371 was involved in keeping the molecule in open conforma-
tion. A mechanism that breaks this bond is necessary for forma-
tion of the active enzyme. We investigated whether disruption of
disulfide bonds by reduction had any effect on the inhibition of
TGM2. The potency of inhibitors listed in Table 3 was signifi-
cantly reduced when DTT was included in the transglutaminase
reaction, suggesting that inhibitors promoted formation of disul-
fide bonds that inactivated the protein. The binding of inhibitors
(Table 3) to Ca+2-activated TGM2 could promote disulfide bond
formation and induce a conformational change that adopts an
open conformation (Pinkas et al., 2007). There is a disulfide
bond formation between Cys370 and Cys371 on inactive inhibi-
tor-bound TGM2 (Pinkas et al., 2007), which locks the protein
into an inactive conformation. DTT reversed the inhibition by in-
hibitors listed in Table 3, suggesting that cysteine thiol(s) in
TGM2 might be the target for these inhibitors. Further studies
are needed to identify which Cys residue(s) were involved and
whether these chemicals lead to specific disulfide bonding that
alter the enzyme’s function. The inhibition by ZM39923 and
ZM449829 was not completely reversed by DTT, suggesting
that they are tight binding inhibitors and may have a more com-
plex mechanism of inhibition (Table 3). The inability of these in-
hibitors to inhibit TGM2 under reducing conditions suggests
that they are likely to be less inhibitory to intracellular TGM2 be-
cause of the presence of intracellular reducing environment.
However, there are many gaps in our knowledge regarding
where and when TGM2 is active.
TGM2 has been recognized as a calcium-dependent enzyme
for many years (Lorand andGraham, 2003). Dialysis experiments
indicated that the chemicals targeted Ca+2-TGM2 (Figure 2). In
the absence of Ca+2, there was only 20%–40% inhibition by
ZM39923, vitamin K3, vitamin K2, and Me-3,4-dephostatin,
whereas >90% inhibition was observed by ZM449829, tyrphos-
tin 47, and NSC95397 (Figure 2A). When TGM2 was incubated
with chemicals in the presence of Ca+2, all inhibitors werelsevier Ltd All rights reserved
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in Rescuing Drosophila in MJD Model of
Neurodegeneration
Chemicals were investigated in these flies at 10
mM. Chemical stocks were diluted to final DMSO
concentrations of %0.1%. Fly food was replen-
ished every 2–3 days. The number of flies left in
the tubes was counted every other day. Untreated
flies (Q78) and flies that carried normal length of
glutamine repeats (Q27) were used as controls.
Each chemical was tested in at least three different
tubes, and the survival rate of flies was calculated
by dividing the number of flies that survived by the
number of starting flies. The log rank p values
compare treated groups and the control (un-
treated) group, as described in Methods. The
standard deviations were derived from triplicate
experiments. ZM: ZM39923; Cyst: cystamine;
Me 3–4: Me-3,4 dephostatin; Q27: elav-Gal4/
Q27; Q78: elav-Gal4-Q78.irreversible (Figure 2B). These data suggest that the inhibitors
prefer Ca+2-activated TGM2 as the target and not inactive
TGM2. Ca+2 induces a conformation that exposes the TGM2 ac-
tive site (Lorand and Graham, 2003). It is likely that a critical cys-
teine thiol, either in the active site Cys277 or in the Cys370–Cys371
disulfide bond, was made accessible by these inhibitors in Ca+2-
TGM2. The reversal of inhibition by DTT suggests that these
chemicals interact directly or indirectly with SH groups that mod-
ulate catalysis. These chemicals do not alter all forms of TGM2,
which may make them potentially less toxic and more selective
by inhibiting calcium-active TGM2.
Competitive fluorescent BODIPY FL-GTP binding assay was
used to investigate whether kinase inhibitors bind to the same
site as GTP (Figure 3). Tyrphostin 47 competed for GTP bind-
ing (Figures 3B and 3C) and partially protected TGM2 from
proteolysis (Supplemental Data). ZM39923, NSC95397, and
Me-3,4-dephostatin did not compete directly for GTP binding
and may bind to another site that plays a role in regulating
catalysis.
Two chemicals designed to target either tyrosine kinases (tyr-
phostin 47) or tyrosine phosphatases (NSC95397 and Me-3,4-
dephostatin) were also found to inhibit TGM2 but did so less po-
tently than ZM39923, which was designed to target Janus kinase
3, suggesting that TGM2 shares a similar kinase-like binding site
(Faaland et al., 1991; Liu, 2003; Peyregne et al., 2005; Prevost
et al., 2003; Suzuki et al., 2001; Tamura et al., 2000; Wolbring
et al., 1994). Tyrphostin compounds target tyrosine kinases by
binding to the kinase substrate binding site (Nowak et al.,
1997). The tyrosine kinase inhibitors used to inhibit TGM2 are
used at 100 mM in most cellular studies (Bain et al., 2003;
Davies et al., 2000); however, our findings suggest Ca-TGM2 is
a target at lower concentrations. The fact that kinase inhibitors
bind and inhibit TGM2 is not unexpected because TGM2 can
bind ATP and function as a kinase (Mishra and Murphy, 2004a,
2006). These findings also indicate that tyrosine itself can be
used as a scaffold in the design of TGase/TGM2 inhibitors. ItChemistry & Biology 15, 969–9was reported that synthetic tyrosine melanin was a good inhibi-
tor of TGase/TGM2 (Ikura et al., 2002).
Several chemicals identified as TGM2 inhibitors were de-
signed to inhibit the kinases and phosphatases in the EGFR
pathway. ZM39923, ZM449829, and NSC95397 inhibit the
Cdc25 phosphatase (Ham et al., 1998), which also targets
EGFR. EGFR is also the target of tyrphostin 47 (Faaland et al.,
1991). Although vitamin K3 does not bind to tyrosine kinase di-
rectly, it is known to activate EGFR tyrosine kinase through inac-
tivation of an unknown regulating tyrosine phosphatase (Klotz
et al., 2002). Furthermore, it is known that EGF induces the
expression of and activates TGM2 in human breast cancer cell
lines (Antonyak et al., 2004). Accordingly, we are currently testing
the effects of these inhibitors on TGM2 expression in breast
cancer.
Several 1,4-naphthoquinones compounds (menadione, also
called vitamin K3, vitamin K2 and NSC 95397) were found to be
TGM2 inhibitors. Quinones represent the largest class of quinoid
compounds, which are widely distributed in nature (Abdelmoh-
sen et al., 2004; Watanabe et al., 2004). Many quinones have
multiple biological functions, including antitumor and carcino-
genic activities. Vitamin K3 (2-methyl-1,4-naphthoquinone) ex-
hibits a broad spectrum of anticancer activity (Lamson and
Plaza, 2003). The vitamin K family of molecules comprises the
natural forms, vitamin K1 (phylloquinone) and vitamin K2 (mena-
quinones), as well as the synthetic form, vitamin K3.
The 1,4-naphthoquinone scaffold present in NSC 95397 and
vitamin K3 was also found to be an irreversible cysteine protease
inhibitor (Valente et al., 2007). The enzymatic mechanism of
TGM2 is similar to that employed by cysteine proteases, involv-
ing a catalytic triad of Cys, His, and Asp (Liu et al., 2002; Peder-
sen et al., 1994). The cysteine thiol group reacts with glutamyl-
containing substrates to form a reactive thioester intermediate,
from which the acyl group is transferred to an amine substrate
(Lorand and Graham, 2003). These data suggest that these in-
hibitors may act directly on the catalytic triad of TGM2.78, September 22, 2008 ª2008 Elsevier Ltd All rights reserved 975
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and an exclusive redox-cycler 2,3-dimethoxy-1,4-naphthoqui-
none (DMNQ) (Abdelmohsen et al., 2003) did not inhibit TGM2
activity, suggesting a specific interaction of vitamin K3, vitamin
K2, NSC 95397, and ZM39923 that was not based solely on non-
specific alkylation. The target of NSC95397, Cdc25A, a dual-
specificity protein phosphatase, plays a critical role in cell cycle
progression (Wang et al., 2002). Cdc25A interacts with EGFR
both physically and functionally in Hep3B human hepatoma cells
(Wang et al., 2002).
The inhibitors identified in this study inhibited the plasma
transglutaminase FXIIIa with IC50 values comparable to TGM2.
In addition, reducing disulfide bond formations prevented the
chemicals from functioning as inhibitors. This suggests they
function by a similar mechanism. FXIII A chain (FXIIIA) is a zymo-
gen and shares 39% amino acid identity with human TGM2 with
the highest degree in the TGase active site pocket and calcium
binding site (Lorand and Graham, 2003). Despite their similarity,
FXIIIa has not been reported to bind nucleotides (Lorand and
Graham, 2003). However, it has been reported that FXIIIa has
kinase activity (Mishra, 2004b), suggesting that it contains a nu-
cleotide binding site. Alternatively, there may be sufficient
homology in FXIIIa to promote the binding that leads to the inhi-
bition at the active site or other SH-dependent site.
The capacity of the TGM2 inhibitors to display in vivo activity
was tested in a Drosophila model of expanded polyQ disease
(Figure 4). Most of the inhibitors tested showed statistically sig-
nificant and beneficial effects in this model, with ZM39923 per-
forming best in rescuing Q78 flies from early death. However,
vitamin K3, a TGM2 inhibitor, did not show any statistically signif-
icant beneficial effects in this model. This may relate to its ineffi-
ciency at entering the CNS, its ability to inhibit species-specific
Drosophila TGM2, or another mechanism. The underlying mech-
anism of action of each inhibitor will require further investigation.
Because these compounds were initially designed to target
other kinases, inhibition of TGM2 activity may not solely explain
the beneficial effects they have in vivo. One possible in vivo
mechanism of action to consider is that when the kinase domain
of TGM2 was occupied by these inhibitors, disulfide bonds
formed that kept TGM2 in a conformation that inhibited the
crosslinking of Q78-containing protein. Current research under-
way will further define how TGM2 inhibitors discovered in this
study function to alter TGM2 catalysis.
SIGNIFICANCE
This study documents that there are inhibitors of TGM2 in
drug libraries. These inhibitors target the Ca+2-activated
form of TGM2. Inhibition depends on disulfide bond forma-
tion because reducing agents interfere with the inhibition.
Oral administration of these agents prevented the prema-
ture death of Drosophila expressing polyQ proteins. To our
knowledge, this is the first example of screening existing
drug libraries for TGM2 inhibitors andmay lead to further ad-
vances in development of orally active TGM2 inhibitors. As
some older drugs have been found to have new uses (Chong
and Sullivan, 2007), our data are significant in providing im-
portant leads to develop more specific inhibitors to TGM2
that can be applied to the devastating neurodegenerative976 Chemistry & Biology 15, 969–978, September 22, 2008 ª2008 Edisease mediated by polyQ-expressing proteins. Our find-
ings may also aid in the development of drugs inhibiting
TGM2-dependent pathology associated with tissue fibrosis,
aging, and organ failure.
EXPERIMENTAL PROCEDURES
Materials
Monoclonal antibodies to human TGM2 (Cub7402) were purchased from Lab
Vision (Fremont, CA). A mouse monoclonal antibody to TGM2, Cub7401, was
obtained as a gift from Dr. P.J. Birckbichler (Birckbichler et al., 1985). 5-Bioti-
namido pentylamine (BP) was obtained from Pierce (Rockford, IL). The LOPAC
and Prestwick libraries were provided by the Duke Center for Chemical Biol-
ogy. Chemicals chosen for further characterization were purchased from
Sigma-Aldrich or Tocris (Ellisville, MO). Chemicals were dissolved in either
100% DMSO or 95% ethanol (vitamin K3 and vitamin K2) and stored at20C.
Expression and Purification of Recombinant TGM2 and Blood
Coagulation Factor XIII A Chains (FXIIIA)
The recombinant TGM2 and FXIIIA were expressed and purified in E. coli as
a GST fusion protein as described previously (Lai et al., 1994, 1998). Protein
concentrations were quantified using the Bradford method (Bio-Rad; Hercu-
les, CA). The recombinant proteins were purified in the presence of reducing
agent DTT, dialyzed against 50 mM Tris-acetate buffer (pH 7.5), 1 mM DTT,
and 15% glycerol, and stored at 80C until ready for use.
Transglutaminase BP Incorporation Assay
TGase/TGM2 activity was determined by quantifying the incorporation of BP
into N,N0-dimethylcasein in a microtiter plate as described previously (Slaugh-
ter et al., 1992). Zymogen FXIIIA was activated with 10 U/ml of thrombin to be-
come FXIIIa at 37C for 20min as described (Lai et al., 1994). The amount of BP
incorporated into the casein was determined after 45 min incubation at 37C
and color developed using streptavidin-conjugated alkaline phosphatase
and para-nitrophenyl phosphate (pNPP) (Slaughter et al., 1992). For IC50 deter-
mination, all assayswere determined in the presence of 1mMBP. For accurate
measurement of IC50, narrower range concentration of inhibitors was chosen
for potent inhibitors. To prevent oxidation, all chemicals were freshly diluted
from 20C stock solution before each assay.
Transglutaminase Fluorescence Assay
The TGase fluorescence assay was used to quantify the incorporation of BOC-
K-EDA-Dansyl (KXD, a K substrate) into N,N0-dimethylcasein (NMC, a Q sub-
strate) (Case and Stein, 2007). In the absence of potential inhibitors, the assay
had a 3-fold increase in fluorescence intensity (lEx 340 nm; lEm 520 nm) when
BOC-K-EDA-Dansyl was crosslinked to N,N0-dimethylcasein.
Fluorescent GTP Binding Assay
The binding assay was performed using a fluorescent GTP analog, BODIPY
FL-GTP (Molecular Probes and Invitrogen; Carlsbad, CA) essentially as de-
scribed (Datta et al., 2006; McEwen et al., 2002). All fluorescence measure-
ments were performed in a cuvette and determined in Molecular Device’s
(Sunnyvale, CA) SpectraMax M2e fluorescence reader. The experiments
were carried out in 50 mM Tris-HCl buffer (pH 7.5) containing 2 mM DTT and
1 mM EDTA. The detection for BODIPY FL-GTP was set at lEx 485 nm and
lEm 520 nm with a l495nm cutoff.
Trypsin Proteolysis of Recombinant TGM2
Purified recombinant GST-TGM2 (1 mg) was incubated with 0.1 mg of trypsin
(L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK) treated and high-
pressure liquid chromatography purified (CalbiochemBiosciences; San Diego,
CA) in the presence of 100 mM free GTP or chemicals, and incubated at 37C
for 1 hr (Lai et al., 1998). The reaction was stopped by the addition of SDS-
PAGE loading buffer. Samples were separated by SDS-PAGE and analyzed
by immunoblotting using the monoclonal antibody Cub7402 against human
TGM2.lsevier Ltd All rights reserved
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Chemical Inhibitors of Tissue TransglutaminaseEffects of Inhibitors in a Drosophila melanogaster Model of
Machado-Joseph Disease
The transgenic fly line bearing the UAS-MJDtr-Q78 transgene has been de-
scribed previously (Warrick et al., 1998). These flies express a carboxy-termi-
nal fragment of the MJD protein containing 78 glutamines with a hemaglutinin
epitope tag at the N terminus, under the control of the GAL4-UAS system. Fly
culture and crosses were performed under standard conditions at 25C. The
fly stocks, including the fly line bearing the elav-GAL4 transgene, were ob-
tained from Model System of Genomics (Department of Biology, Duke Univer-
sity). Instant Drosophila medium (Carolina Biological Supply; Burlington, NC)
was used. We used flies expressing expanded polyglutamine (78 glutamine
repeats, designated as Q78) as disease flies and flies carrying Q27 domain as
normal flies (Popiel et al., 2007). Compounds were investigated in these flies
at 10 mM. Chemical stocks were diluted to 10 mM in DMSO and 1:1,000
with sterile 5% sucrose solution. Then 3.33 parts solution was added to one
part solid flake food (formula-4-24; Carolina Biological Supply) and mixed.
We found 0.7% DMSO is toxic at some level for flies, so the final DMSO con-
centrations were%0.1%. Fly food was replenished every 2–3 days. The num-
ber of flies left in the tubes was counted every other day. Untreated flies (Q78)
and living flies that carried normal length of glutamine repeats (Q27) were used
as controls. Each chemical was tested for at least 50 flies divided in three or
more separate test tubes (i.e., triplicate for each chemical). The survival rate
of flies was calculated as a percentage of flies remaining in the tubes at the
end of test period. Survival functions were modeled using the Kaplan-Meier
method as implemented in SAS version 9.1.3 (SAS; Cary, NC). Comparisons
between treatment groups were made using the log rank test. Statistical sig-
nificance was declared at p < 0.05.
SUPPLEMENTAL DATA
Supplemental Data include one figure and five tables and can be found with
this article online at http://www.chembiol.com/cgi/content/full/15/9/969/
DC1/.
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